Communiqués CSPC Pharmaceutical Group Limited

Actions

1093

HK1093012172

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:15 03/07/2026			Varia. 5j.	Varia. 1 janv.
8,000 ^HKD	+5,96%		+19,58%	-5,10%

02/07	Les bourses europeennes bondissent, le petrole recule ; rallye des secteurs de la defense et du luxe	MT
02/07	CSPC Pharma lance un essai clinique pour un traitement oncologique en Chine	MT

Communiqués

19/02/25	Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate	AQ
08/10/24	AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy	AQ
01/09/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "OSELTAMIVIR PHOSPHATE CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL	PU
12/05/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "ALOGLIPTIN BENZOATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL	PU
12/05/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "SORAFENIB TOSYLATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL	PU
12/05/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR "DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION"	PU
12/05/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "SITAGLIPTIN PHOSPHATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL	PU
07/05/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL FIRST-IN-CLASS PRODUCT SYSA1801 GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA	PU
30/04/21	CSPC Pharmaceutical : CONNECTED TRANSACTION - DISPOSAL OF 49.5% EQUITY INTEREST IN JOINT VENTURE COMPANY /CONTINUING CONNECTED TRANSACTIONS - MASTER PURCHASE AGREEMENT	PU
26/04/21	CSPC Pharmaceutical : INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2021	PU
23/04/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - NBL-012 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA	PU
20/04/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - APPLICATION FOR MARKETING APPROVAL OF "DUVELISIB CAPSULES" ACCEPTED BY NMPA	PU
14/04/21	PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 18 MAY 2021 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF)	PU
14/04/21	CSPC Pharmaceutical : PROPOSALS FOR GENERAL MANDATES TO BUY-BACK SHARES AND TO ISSUE SHARES AND MANDATE TO GRANT OPTIONS, RE-ELECTION OF THE RETIRING DIRECTORS, AND NOTICE OF ANNUAL GENERAL MEETING	PU
09/04/21	CSPC Pharmaceutical : INVESTIGATIONAL NEW DRUG NBL-015 GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA	PU
01/04/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL	PU
30/03/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF "DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)"	PU
29/03/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.	PU
25/03/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA	PU
15/03/21	CSPC Pharmaceutical : ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020	PU
09/03/21	CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AND COMMERCIALIZATION AGREEMENT	PU
05/03/21	CSPC Pharmaceutical : APPOINTMENT AND RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS	PU
04/03/21	CSPC Pharmaceutical : INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 December 2020	PU
22/09/20	CSPC Pharmaceutical : NOTICE OF EXTRAORDINARY GENERAL MEETING	PU
22/09/20	PROXY FORM FOR USE AT THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, 12 OCTOBER 2020 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF)	PU